N-甲酰基-Met-Leu-Phe-Lys | 104180-18-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲酰基-Met-Leu-Phe-Lys
• 英文名称: N-Formylmethionylleucylphenylalanyllysine
• 英文别名: 6-amino-2-[[2-[[2-[(2-formamido-4-methylsulfanylbutanoyl)amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid
• CAS: 104180-18-9
• 化学式: C₂₇H₄₃N₅O₆S
• 分子量: 565.7
• InChiKey: OERILMBTPCSYNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  39
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  205
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Chemotactic peptide antagonists for imaging sites of inflammation
  申请人：Roe David

  公开号：US20050100507A1

  公开（公告）日：2005-05-12

  Radiopharmaceuticals comprising molecules that target to N-formyl-methionyl-leucyl-phenylalanine (fMLF) receptor on leukocytes in order to target sites of inflammation for diagnostic imaging are described. The targeting molecules are attached to capping groups that make the entire molecule either antagonists or weak agonists of fMLF receptor and therefore do not elicit a chemotactic response resulting in neutropenia. The preferred targeting molecule is ReO-Gly-lys(Dimethylgly-t-Butylgly-cys-gly)-glu-trp-phe-leu-nle-NHCOcyclopropyl. The invention also relates to the use of combinatorial chemistry to obtain preferred molecules that target sites of inflammation for diagnostic imaging.

  本研究描述了由靶向白细胞上的 N-甲酰基-蛋氨酰-亮氨酰-苯丙氨酸（fMLF）受体的分子组成的放射性药物，以便针对炎症部位进行诊断成像。靶向分子附有封端基团，使整个分子成为 fMLF 受体的拮抗剂或弱激动剂，因此不会引起导致中性粒细胞减少的趋化反应。优选的靶向分子是 ReO-Gly-lys(Dimethylgly-t-Butylgly-cys-gly)-glu-trp-phe-leu-nle-NHCOcyclopropyl。本发明还涉及使用组合化学方法获得优选的靶向炎症部位的分子，用于诊断成像。
• Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions
  申请人：Fischman Alan

  公开号：US20060073100A1

  公开（公告）日：2006-04-06

  The present invention relates to methods for selectively targeting Photodynamic Therapy (“PDT”) to inflammatory components of vulnerable plaques. As such, the present invention provides methods for the identification of vulnerable plaques, using fluorescent compositions, which include photosensitizer compoisitions, and/or radiolabeled compounds, as well as methods to treat vulnerable plaques by selectively targeting and/or eliminating the inflammatory components of vulnerable plaques.

  本发明涉及选择性地将光动力疗法（"PDT"）靶向易损斑块的炎症成分的方法。因此，本发明提供了使用荧光组合物（包括光敏剂组合物和/或放射性标记化合物）识别易损斑块的方法，以及通过选择性靶向和/或消除易损斑块的炎症成分来治疗易损斑块的方法。
• LABELED CHEMOTACTIC PEPTIDES TO IMAGE FOCAL SITES OF INFECTION OR INFLAMMATION
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP0732944A1

  公开（公告）日：1996-09-25
• EP0732944A4
  申请人：——

  公开号：EP0732944A4

  公开（公告）日：2000-06-07
• US5792444A
  申请人：——

  公开号：US5792444A

  公开（公告）日：1998-08-11